Synapse Medicine raised €25 million in an equity round led by Korelya Capital.

Synapse Medicine, a Bordeaux, France-based creator of a ‘medication intelligence platform’ dedicated to correct drug use, raised an equity round closed at €25 million ($28M).

The money was raised from investors led by Korelya Capital, and joined by MACSF, XAnge and BNP Paribas.

Synapse Medicine, founded in 2017 by CEO Clément Goehrs, delivers easily accessible, reliable and up-to-date drug information via a tool that is used to analyze and classify medication information from several sources — medication documentation from manufacturers, official recommendations from health authorities, and results from research papers. The solution is sold as a standalone software-as-a-service product or as an extension to your existing Electronic Health Record (EHR) solution.

Prior to this round, Synapse Medicine raised $8 million from investors led by the MACSF.